<\/p>\n
Tempus AI (TEM) spent three years selling someone else’s cancer test. On Monday, July 20, it decided to just buy the whole thing.<\/p>\n
The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion.\u00a0<\/p>\n
The move hands Tempus full control of a test that spots cancer coming back before a scan ever could.<\/p>\n
Investors did not treat it as a win. Tempus stock dropped, and it has kept sliding since.<\/p>\n
That gap between the strategy and the stock price is worth understanding. Wall Street likes the deal. It just does not want to pay for it yet.<\/p>\n
What Tempus is buying with the Personalis deal<\/p>\n
According to a Tempus press release, the company is paying $16.25 per share for Personalis, valuing the company at $1.5 billion, including debt.\u00a0<\/p>\n
That works out to a 6% increase over the prior Friday, July 17, close and a 28% jump against the 30-day average price.<\/p>\n
More Tech Stocks:<\/p>\n
Cathie Wood buys $36.1 million of tumbling tech stockCiti revamps Microsoft stock price target for the rest of 2026Top-rated analyst sets a jaw-dropping Intel stock price target<\/p>\n
The prize is a test called NeXT Personal. It tracks tiny fragments of tumor DNA in the blood to catch what doctors call minimal residual disease, or MRD.<\/p>\n
MRD is the cancer that lingers after surgery or chemo and hides below the reach of normal scans.<\/p>\n
The two companies have worked together previously.\u00a0Tempus invested in Personalis back in November 2023 and has sold the test through its own sales force ever since, according to Reuters.\u00a0<\/p>\n
This deal turns that partnership into ownership.<\/p>\n
Tempus is buying full control of an ultra-sensitive test that detects cancer left behind after treatment.<\/p>\n
SOPA Images / Getty Images<\/p>\n
Why owning the whole cancer test matters more than sharing it<\/p>\n
Under the old setup, Tempus split the money from every NeXT Personal test it sold. Full ownership means every dollar now flows to one place.<\/p>\n
That matters because the market is large. Tempus and Personalis peg the MRD opportunity at roughly $20 billion, and fewer than 10% of eligible patients are tested today, according to MedCity News.<\/p>\n
The test is also selling fast. Personalis reported preliminary second-quarter revenue of $22.4 million.<\/p>\n
The company also ran 10,384 clinical tests, which is a 33% jump in volume from the prior quarter, Quartz reported.<\/p>\n
The data engine behind the deal<\/p>\n
There is a second reason for Tempus to own Personalis outright.<\/p>\n
Tempus sits on a library of more than 8 million de-identified patient records, and it rents access to that data to drugmakers.\u00a0The company’s SEC filing showed that Insights, which is Tempus\u2019 data-licensing arm, grew about 44% in the first quarter.<\/p>\n
Folding Personalis genomic data into that library makes the whole thing more valuable to drugmaker partners.\u00a0AstraZeneca (AZN), for instance, is paying Tempus up to $200 million across a multi-year model-building deal, Fierce Biotech noted.\u00a0<\/p>\n
GSK is another. More data means more leverage in those contracts.<\/p>\n
In plain terms, Tempus is not just buying a test. It is also buying more of the raw material its most profitable business runs on.<\/p>\n
Why Tempus stock fell, even though the logic holds<\/p>\n
If the strategy is sound, why did the stock drop close to 9% on the day and keep falling to about $49 by Tuesday, July 21?<\/p>\n
The answer comes down to how the deal gets paid for.<\/p>\n
This is mostly a stock transaction, which means Tempus will issue new shares to Personalis holders.\u00a0<\/p>\n
Related: UnitedHealth CFO sends stark warning after earnings<\/p>\n
New shares dilute existing owners, and markets tend to punish that first and ask questions later, according to TipRanks.<\/p>\n
Tempus can also pay up to half in cash. If it does, that cash comes from its balance sheet and credit lines, and the company already carries a debt-to-equity ratio of around 2.45.<\/p>\n
The timing problem investors are stuck on<\/p>\n
There is also a timing concern. The deal is not expected to close until late 2026 or early 2027, pending a Personalis shareholder vote and regulatory sign-off.<\/p>\n
That means investors absorb the dilution risk now and wait more than a year for the benefits, Benzinga reported.<\/p>\n
Tempus was already tracking toward adjusted EBITDA of about $65 million for 2026, a milestone that signals the business is nearing self-sustaining cash generation.\u00a0<\/p>\n
Absorbing Personalis costs could delay that milestone.<\/p>\n
What Wall Street analysts still see in Tempus<\/p>\n
Here is the part that complicates the sell-off. The analysts who cover Tempus mostly ignored the drop.<\/p>\n
Morgan Stanley called the case compelling and pointed out that about 80%of Personalis clinical volume already runs through Tempus channels, according to Stocktwits.\u00a0<\/p>\n
That limits the integration mess that usually affects acquisitions.<\/p>\n
Needham kept its buy rating and a $75 target, according to Investing.com.\u00a0<\/p>\n
The average price target across 15 analysts sits at $65.77, well above where the stock trades now.<\/p>\n
The bull case, in plain terms<\/p>\n
For the outlook to work from here, a few things need to line up.<\/p>\n
The deal closes on schedule without regulators forcing changes.MRD testing keeps growing volume the way it did last quarter.The data-licensing business keeps signing pharma deals.Tempus holds its path toward positive adjusted EBITDA, despite the added costs.<\/p>\n
None of those are guaranteed. The stock trades below its 52-week high of $104.32 for a reason, and a company still posting losses has less room for a misstep.<\/p>\n
How Tempus stock stacks up right now<\/p>\n
Tempus shares have had a rough stretch. The stock is down about 16% over the past five trading days and roughly 21% from the start of the year. It is now trading near $49.39.<\/p>\n
That is a long way from the highs, but it also sits above the 52-week low of $41.73.<\/p>\n
The next real test is approaching soon.\u00a0<\/p>\n
Tempus reports earnings on July 30, and management will field direct questions about how it plans to pay for Personalis without stalling its own profitability, Benzinga noted.<\/p>\n
What this means for investors watching Tempus<\/p>\n
The Personalis deal gives Tempus something rare: a leading position in a market that is barely tapped, and a richer data set to sell to the world’s biggest drugmakers, Bloomberg reported.<\/p>\n
The payoff will not show up soon. Investors have to accept dilution and a heavier debt load now, in hopes of a market that pays off in 2027 and beyond.<\/p>\n
Long-term holders who buy the AI-and-oncology outlook may see the drop as noise around a sound strategy.<\/p>\n
Anyone focused on the next few quarters should watch the earnings call on July 30. It will say more than the deal announcement did.<\/p>\n
Either way, watch the gap between what Tempus is building and what its stock is doing. That gap is the clearest signal on the table right now.<\/p>\n
Related: Stanford Health AI Week: How AI Can Support Aging in Place<\/p>\n
#Tempus #1.5B #bet #corner #cancertest #market<\/p>\n","protected":false},"excerpt":{"rendered":"
Tempus AI (TEM) spent three years selling someone else’s cancer test. On Monday, July 20,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[17716,157,17717,2741,33,17715],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/11782"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11782"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/11782\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}